The aim of this study was to determine whether pathogenic heterozygous germline variants in the BRCA1/2 genes confer increased chromosomal radiosensitivity compared with measurements of chromosomal radiosensitivity in a cohort of generally healthy individuals, patients with rectal cancer and patients with breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.